Vimarsana
Biggest News Aggregation in the World

Page 19 - Pharma Services News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pharma Services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pharma Services Today - Breaking & Trending Today

Indiana's new federal Tech Hub designation is met with bipartisan celebration - Vimarsana News

Indiana's new federal Tech Hub designation is met with bipartisan celebration

This week, the U.S. Department of Commerce’s Economic Development Administration announced that Indiana-based Heartland BioWorks, a consortium led by the Applied Research Institute, has been designated as a Regional Technology

President Biden naming 'tech hubs' for 32 states, including Indiana - Vimarsana News

President Biden naming 'tech hubs' for 32 states, including Indiana

The Biden administration is designating "tech hubs" for Indiana and 31 other states to help spur innovation and create jobs.

Source: wishtv.com
Aldena chooses PCI to manufacture injectable dermatological treatment - Vimarsana News

Aldena chooses PCI to manufacture injectable dermatological treatment

Aldena Therapeutics has selected PCI for manufacturing and distributing of ALD-102, an investigational treatment for dermatological diseases.

Aldena Therapeutics Selects PCI Pharma Services to Manufacture and Distribute Innovative Investigational Treatment for Dermatological Diseases - Vimarsana News

Aldena Therapeutics Selects PCI Pharma Services to Manufacture and Distribute Innovative Investigational Treatment for Dermatological Diseases

CSG NASDAQ CSGS empowers companies to build unforgettable digital experiences with consumers and businesses alike.

NeoGenomics (NASDAQ:NEO) PT Lowered to $18.00 - Vimarsana News

NeoGenomics (NASDAQ:NEO) PT Lowered to $18.00

NeoGenomics (NASDAQ:NEO – Free Report) had its price target lowered by Piper Sandler from $23.00 to $18.00 in a report released on Monday, Benzinga reports. Piper Sandler currently has an overweight rating on the medical research company’s stock. A number of other brokerages also recently issued reports on NEO. Morgan Stanley cut their price objective […]

Source: wkrb13.com